Vaxart (VXRT) News Today $0.74 0.00 (-0.20%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average - Time to Sell?Vaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - Should You Sell?January 17 at 11:21 PM | marketbeat.comVaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Stock Passes Below 200-Day Moving Average - Here's WhyJanuary 16, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving Average - What's Next?Vaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average - Here's What HappenedJanuary 16, 2025 | marketbeat.comVaxart highlights progress of COVID-19, norovirus, influenza programsJanuary 14, 2025 | markets.businessinsider.comVaxart Announces Favorable DSMB Review To Continue COVID-19 Phase 2b Trial; Stock UpJanuary 14, 2025 | markets.businessinsider.comVaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical TrialJanuary 13, 2025 | globenewswire.comVaxart project agreement change ups funding for oral COVID vaccine candidateDecember 28, 2024 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average - What's Next?Vaxart (NASDAQ:VXRT) Stock Price Passes Below 200 Day Moving Average - Here's WhyDecember 21, 2024 | marketbeat.comVaxart (NASDAQ:VXRT) Stock Price Crosses Below Two Hundred Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average - Time to Sell?December 13, 2024 | marketbeat.comVaxart completes enrollment in Phase 2b study evaluating its COVID-19 pillDecember 3, 2024 | markets.businessinsider.comVaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateDecember 2, 2024 | globenewswire.comSio Capital Management LLC Decreases Holdings in Vaxart, Inc. (NASDAQ:VXRT)Sio Capital Management LLC lowered its holdings in Vaxart, Inc. (NASDAQ:VXRT - Free Report) by 7.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,608,244 shares of the biotechnology compNovember 29, 2024 | marketbeat.comB. Riley Forecasts Vaxart's FY2024 Earnings (NASDAQ:VXRT)Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Investment analysts at B. Riley raised their FY2024 earnings per share estimates for shares of Vaxart in a research note issued to investors on Monday, November 18th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnNovember 21, 2024 | marketbeat.comFY2027 Earnings Estimate for Vaxart Issued By B. RileyVaxart, Inc. (NASDAQ:VXRT - Free Report) - Stock analysts at B. Riley issued their FY2027 earnings estimates for shares of Vaxart in a research report issued to clients and investors on Monday, November 18th. B. Riley analyst M. Mamtani forecasts that the biotechnology company will earn $0.09 perNovember 20, 2024 | marketbeat.comVaxart reports inducement grants under Nasdaq listing ruleNovember 20, 2024 | markets.businessinsider.comVaxart’s Promising Advancements in Oral Vaccine Development and Norovirus Program Drive Buy RatingNovember 19, 2024 | markets.businessinsider.comVaxart (VXRT) Receives a Buy from OppenheimerNovember 14, 2024 | markets.businessinsider.comVaxart’s Q3 2024: Progress in Oral Vaccine DevelopmentNovember 14, 2024 | markets.businessinsider.comVaxart, Inc. (VXRT) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comVaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | globenewswire.comVaxart (VXRT) to Release Earnings on WednesdayVaxart (NASDAQ:VXRT) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 8, 2024 | marketbeat.comVaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13November 7, 2024 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Stock Price Passes Below 200 Day Moving Average - Time to Sell?Vaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving Average - Here's What HappenedNovember 1, 2024 | marketbeat.comVaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024October 24, 2024 | markets.businessinsider.comVaxart will present research on COVID-19, norovirus vaccine candidatesOctober 24, 2024 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - Time to Sell?October 24, 2024 | marketbeat.comVaxart, Inc. (NASDAQ:VXRT) Shares Purchased by Millennium Management LLCMillennium Management LLC grew its stake in shares of Vaxart, Inc. (NASDAQ:VXRT - Free Report) by 110.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,985,670 shares of the biotechnology company's stock after purchasinOctober 16, 2024 | marketbeat.comOppenheimer Sticks to Their Buy Rating for Vaxart (VXRT)October 3, 2024 | markets.businessinsider.comVaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateSeptember 30, 2024 | globenewswire.comVaxart (NASDAQ:VXRT) Stock Price Crosses Above 200-Day Moving Average of $0.84Vaxart (NASDAQ:VXRT) Shares Pass Above 200 Day Moving Average of $0.84September 26, 2024 | marketbeat.comVaxart (NASDAQ:VXRT) Stock Passes Above 200-Day Moving Average of $0.85Vaxart (NASDAQ:VXRT) Stock Price Crosses Above 200-Day Moving Average of $0.85September 18, 2024 | marketbeat.comMonaco Asset Management SAM Makes New $402,000 Investment in Vaxart, Inc. (NASDAQ:VXRT)Monaco Asset Management SAM purchased a new position in shares of Vaxart, Inc. (NASDAQ:VXRT - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 601,700 shares of the biotechnologySeptember 10, 2024 | marketbeat.comVaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average of $0.88Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average of $0.88September 3, 2024 | marketbeat.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 30, 2024 | globenewswire.comVaxart's Pre-clinical Data Reveals Potential Of Mucosal Vaccine Platform For HPV- Cervical DysplasiaAugust 29, 2024 | markets.businessinsider.comFY2024 EPS Estimates for Vaxart, Inc. (NASDAQ:VXRT) Lifted by AnalystVaxart, Inc. (NASDAQ:VXRT - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for shares of Vaxart in a research note issued to investors on Thursday, August 22nd. Cantor Fitzgerald analyst C. Duncan now expects that the biotechnology company will post earnings of ($August 26, 2024 | marketbeat.comVaxart’s Promising Vaccine Pipeline: Leading in Mucosal Immunity with Government Support and Competitive AdvantagesAugust 16, 2024 | markets.businessinsider.comVanguard Group Inc. Acquires 1,404,391 Shares of Vaxart, Inc. (NASDAQ:VXRT)Vanguard Group Inc. grew its holdings in Vaxart, Inc. (NASDAQ:VXRT - Free Report) by 19.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,449,362 shares of the biotechnology company's stock after acqAugust 15, 2024 | marketbeat.comVXRT Stock Earnings: Vaxart Misses EPS, Beats Revenue for Q2 2024August 8, 2024 | investorplace.comVaxart Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comVaxart (VXRT) to Release Quarterly Earnings on ThursdayVaxart (NASDAQ:VXRT) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports.August 3, 2024 | marketbeat.comVaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8August 2, 2024 | globenewswire.comVaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving Average of $0.92Vaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average of $0.92July 31, 2024 | marketbeat.comVaxart (NASDAQ:VXRT) Stock Passes Below 200-Day Moving Average of $0.91Vaxart (NASDAQ:VXRT) Stock Crosses Below Two Hundred Day Moving Average of $0.91July 9, 2024 | marketbeat.comVaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average of $0.90Vaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average of $0.90June 28, 2024 | marketbeat.comVaxart, Inc. (NASDAQ:VXRT) Director W. Mark Watson Acquires 20,000 SharesJune 21, 2024 | insidertrades.comVaxart Provides Business UpdateJune 17, 2024 | globenewswire.comVaxart Announces $40 Million Underwritten Offering of Common StockJune 13, 2024 | globenewswire.comVaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateJune 13, 2024 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average of $0.91Vaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average of $0.91June 11, 2024 | marketbeat.com Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Media Mentions By Week VXRT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VXRT News Sentiment▼0.540.44▲Average Medical News Sentiment VXRT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VXRT Articles This Week▼51▲VXRT Articles Average Week Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 89bio News Today Evolus News Today Bicara Therapeutics News Today Immatics News Today Immunome News Today Ginkgo Bioworks News Today LENZ Therapeutics News Today Arbutus Biopharma News Today Tectonic Therapeutic News Today Cullinan Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VXRT) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VXRT Stock Alerts